<DOC>
	<DOCNO>NCT00001025</DOCNO>
	<brief_summary>To determine relationship viral susceptibility zidovudine ( AZT ) baseline viral load ( determine plasma viremia quantitative endpoint dilution ) . To determine relationship viral load susceptibility different antiretroviral therapy strategy . To correlate measure viral load short term clinical laboratory marker ( weight , CD4 count , p24 antigenemia , beta2 microglobulin ) different therapy arm . High-grade resistance AZT detect HIV isolates approximately 25 percent individual AIDS receive AZT least 1 year . To elucidate clinical significance vitro AZT resistance , necessary distinguish clinical failure cause AZT resistance clinical decompensation cause factor .</brief_summary>
	<brief_title>Evaluation Patients Who Have Not Had Success With Zidovudine</brief_title>
	<detailed_description>High-grade resistance AZT detect HIV isolates approximately 25 percent individual AIDS receive AZT least 1 year . To elucidate clinical significance vitro AZT resistance , necessary distinguish clinical failure cause AZT resistance clinical decompensation cause factor . One hundred-twenty patient receive AZT least 1 year randomize 1 ) continue AZT , 2 ) switch treatment didanosine 1 2 dos , 3 ) receive AZT ddI . Treatment give 16 week , possible extension 32 week . Patients follow week 2 , 4 , 8 , 12 , 16 . For analysis purpose , patient stratify accord degree susceptibility HIV isolate AZT .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chemoprophylaxis Pneumocystis carinii pneumonia ( PCP ) , Mycobacterium tuberculosis , Herpes simplex virus , opportunistic infection indicate . Corticosteroids longer 21 day ( part PCP therapy ) . Erythropoietin GCSF . Patients must : Documented HIVseropositivity . CD4 count 100 300 cells/mm3 . Prior continuous AZT dose = &gt; 300 mg/day 1 year longer . Prior Medication : Required : AZT least 1 year prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Medical contraindication consider noncompliant opinion investigator . Peripheral neuropathy = &gt; grade 2 . Concurrent Medication : Excluded : AntiHIV agent study drug . Biologic response modifier ( erythropoietin GCSF ) . Systemic cytotoxic chemotherapy . Regularly prescribed medication ( antipyretic , analgesic , allergy medication ) associate increase risk pancreatitis , peripheral neuropathy , bone marrow suppression . Concurrent Treatment : Excluded : Radiation therapy . Patients follow prior condition exclude : History acute chronic pancreatitis , gout , uric acid nephropathy . Prior Medication : Excluded : Other antiretrovirals besides AZT . ddI ddC 30 day within past year time within 3 month prior study entry . Acute therapy infection medical illness within 14 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Virus Replication</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>